$INCY News

Incyte (NASDAQ:INCY) Q3 Beat Overshadowed by Below-Consensus Sales Guidance

Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

Incyte’s (NASDAQ:INCY) Q3 2026 sales beat estimates but full-year sales guidance misses expectations significantly

Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates

Incyte: Q3 Earnings Snapshot

Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates

Incyte Q3 2026 Earnings Call Transcript

Incyte Raises FY2026 Sales Guidance from $5.130B-$5.260B to $5.210B-$5.300B vs $5.929B Est

Incyte Q3 Adj. EPS $(3.60) Beats $(3.85) Estimate, Sales $1.557B Beat $1.470B Estimate

Incyte (INCY) reports Q3: everything you need to know ahead of earnings

Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs - Slideshow

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript

Incyte Highlights Promising Early Data for ’890 and ’734 in GI Cancers

Incyte Corporation (INCY) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow

Is Incyte (INCY) Cheap After A 120% Three Year Run?

Incyte (INCY) Heads To ESMO With New Oncology Data, Is The Stock Still Undervalued?

Analysts Estimate Incyte (INCY) to Report a Decline in Earnings: What to Look Out for

TD Cowen Maintains Buy on Incyte, Raises Price Target to $140

Incyte: Digesting The ESMO Updates In Pancreatic, Colorectal, And Ovarian Cancer